10.6084/m9.figshare.c.3688210_D2.v1
Antonino Musolino
Antonino
Musolino
Mario Campone
Mario
Campone
Patrick Neven
Patrick
Neven
Neelima Denduluri
Neelima
Denduluri
Carlos Barrios
Carlos
Barrios
Javier Cortes
Javier
Cortes
Kimberly Blackwell
Kimberly
Blackwell
Hatem Soliman
Hatem
Soliman
Zsuzsanna Kahan
Zsuzsanna
Kahan
HervĂŠ Bonnefoi
HervĂŠ
Bonnefoi
Matthew Squires
Matthew
Squires
Yong Zhang
Yong
Zhang
Stephanie Deudon
Stephanie
Deudon
Michael Shi
Michael
Shi
Fabrice AndrĂŠ
Fabrice
AndrĂŠ
Additional file 2: Table S1. of Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2â breast cancer that had progressed during or after prior endocrine therapy
Springer Nature
2017
Dovitinib
TKI285
Fulvestrant
FGF
FGFR
Breast cancer
Endocrine resistance
2017-02-10 05:00:00
Journal contribution
https://springernature.figshare.com/articles/journal_contribution/Additional_file_2_Table_S1_of_Phase_II_randomized_placebo-controlled_study_of_dovitinib_in_combination_with_fulvestrant_in_postmenopausal_patients_with_HR_HER2_breast_cancer_that_had_progressed_during_or_after_prior_endocrine_therapy/4640344
Dose changes and dose delays by treatment arm. Table S2. Adverse events leading to study drug discontinuation regardless of study drug relationship. Table S3. Study center. (DOCX 17Â kb)